Head to Head Comparison: Novocure (NVCR) versus Utah Medical Products (UTMD)

Novocure (NASDAQ:NVCR) and Utah Medical Products (NASDAQ:UTMD) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, earnings, valuation, profitability, analyst recommendations and dividends.

Analyst Ratings

This is a summary of recent ratings and target prices for Novocure and Utah Medical Products, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Novocure 0 1 5 0 2.83
Utah Medical Products 0 0 0 0 N/A

Novocure presently has a consensus price target of $48.33, indicating a potential upside of 7.31%. Given Novocure’s higher possible upside, analysts plainly believe Novocure is more favorable than Utah Medical Products.


This table compares Novocure and Utah Medical Products’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Novocure -26.99% -52.34% -20.57%
Utah Medical Products 22.52% 19.13% 16.48%

Valuation & Earnings

This table compares Novocure and Utah Medical Products’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Novocure $177.03 million 23.64 -$61.66 million ($0.70) -64.34
Utah Medical Products $41.41 million 7.87 $8.50 million N/A N/A

Utah Medical Products has lower revenue, but higher earnings than Novocure.


Utah Medical Products pays an annual dividend of $1.08 per share and has a dividend yield of 1.2%. Novocure does not pay a dividend. Utah Medical Products has increased its dividend for 7 consecutive years.

Insider and Institutional Ownership

56.1% of Novocure shares are owned by institutional investors. Comparatively, 69.3% of Utah Medical Products shares are owned by institutional investors. 15.3% of Novocure shares are owned by insiders. Comparatively, 8.8% of Utah Medical Products shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility and Risk

Novocure has a beta of 3.29, suggesting that its stock price is 229% more volatile than the S&P 500. Comparatively, Utah Medical Products has a beta of 0.42, suggesting that its stock price is 58% less volatile than the S&P 500.


Utah Medical Products beats Novocure on 8 of the 14 factors compared between the two stocks.

Novocure Company Profile

NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline. In addition to its clinical and commercial progress in GBM, it is planning or conducting clinical trials evaluating the use of TTFields in brain metastases, non-small-cell lung cancer (NSCLC), pancreatic cancer, ovarian cancer and mesothelioma. TTFields are delivered through a portable, medical device. The complete delivery system, which is designed to allow patients to go about their daily activities while receiving continuous cancer treatment, includes a portable electric field generator, transducer arrays, rechargeable batteries and accessories.

Utah Medical Products Company Profile

Utah Medical Products, Inc. develops, manufactures, and distributes medical devices for the healthcare industry worldwide. The company offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD, an infant respiratory hood; and DELTRAN PLUS, a blood pressure monitoring system. It also provides umbilical vessel catheters; DIALY-NATE, a disposable peritoneal dialysis set; PALA-NATE, a silicone oral protection device; URI-CATH, a urinary drainage system; MYELO-NATE, a lumbar sampling kit; and HEMO-NATE, a disposable filter. In addition, the company offers LETZ system to excise cervical intraepithelial neoplasia; FINESSE+ generators; loop, ball, and needle electrodes; FILTRESSE evacuators; other specialty electrodes and UTMD supplies, and gynecologic tools; Femcare trocars and cannulae; Femcare laparoscopic instruments and accessories; and EPITOME, an electrosurgical scalpel. Further, it provides FILSHIE CLIP system, a female surgical contraception; PATHFINDER PLUS, an endoscopic irrigation device; suprapubic catheterization; LIBERTY system to treat and control urinary incontinence in women; ENDOCURETTE, a curette for uterine endometrial tissue sampling; TVUS/HSG-Cath to assess abnormal or dysfunctional uterine bleeding and other suspected abnormalities of the uterus; and LUMIN to manipulate the uterus in laparoscopic procedures. Additionally, the company offers DELTRAN, a disposable pressure transducer; and pressure monitoring accessories, components, and other molded parts. It markets its products to neonatal intensive care unit, labor and delivery department, women's health center in hospitals, outpatient clinics, and physician's offices. The company sells its products through customer service and sales force, independent consultants, and independent manufacturer representatives. Utah Medical Products, Inc. was founded in 1978 and is headquartered in Midvale, Utah.

Receive News & Ratings for Novocure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novocure and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply